Researcher Spotlight: Ryan Lynch, MD University of Washington Checkpoint inhibitors, a type of immunotherapy, have been approved for patients with relapsed Hodgkin lymphoma (HL); however, they do not lead to durable remissions in most patients. Dr. Lynch’s LRF grant project…
Researcher Spotlight: Adam Lin, MD, PhD Northwestern University Feinberg School of Medicine Many immunotherapies and cell therapies on the market have increased the cure rate for patients with non-Hodgkin lymphoma (NHL); however, the percentage of relapse and death continues to…
Researcher Spotlight: Abi Vijenthira, MD University Health Network Lymphoma is the most common blood cancer in Canada, and diffuse large B-cell lymphoma (DLBCL) has the greatest incidence in older patients compared to all other lymphomas. Older patients are at risk…
Researcher Spotlight: Christopher Strouse, MD The University of Iowa Follicular lymphoma (FL) is typically an indolent, or slow-growing, form of non-Hodgkin lymphoma accounts for 20 to 30 percent of all cases on non-Hodgkin lymphoma. Patients diagnosed with FL can typically…
Researcher Spotlight: Raphael Eric Steiner, MD University of Texas MD Anderson Cancer Center Primary mediastinal large B-cell lymphoma (PMLBCL), a type of diffuselarge B-cell lymphoma (DLBCL), affects predominantly adolescents and young adults and is usually treated with chemo-immune therapy with…
Researcher Spotlight: Christina Lee, MD Memorial Sloan Kettering Cancer Center It has become increasingly apparent that normal immune cells are important in disease progression and therapy resistance in lymphoma. Studies from a clinical trial of two targeted therapies, ibrutinib (Imbruvica)…
Researcher Spotlight: Boyu Hu, MD University of Utah/Huntsman Cancer Institute Gene mutations and chromosomal alterations found in relapsed/refractorychronic lymphocytic leukemia (CLL) makes the disease more resistant to currently approved therapies and prone to earlier relapses. While these gene changes are…
Researcher Spotlight: Jamie Flerlage, MD St. Jude Children’s Research Hospital, Inc. Nodular lymphocyte-predominant Hodgkin lymphoma(NLPHL) is a rare type of Hodgkin lymphoma (HL) thattends to grow more slowly than HL and requires differenttreatment. Despite its high cure rates, NLPHL is…
Researcher Spotlight: Pamela Allen, MD Emory University/Winship Cancer Institute Patients with advanced-stage cutaneous T-cell lymphoma (CTCL) have a median survival of fewer than five years and often experience debilitating itchy red skin. Patients with CTCL may be treated with extracorporeal…
